BlackRock Inc. Takes $140.34 Million Position in Palvella Therapeutics, Inc. $PVLA

Key Points

• BlackRock acquired 918,357 Palvella Therapeutics shares worth approximately $140.34 million, giving it a 6.37% stake. Institutional investors collectively own 40.11% of PVLA.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and an average price target of $209.14, despite ratings ranging from “Sell” to “Strong Buy.”
• Palvella shares opened at $149.97, near their 12-month high, while the company reported a quarterly loss of $1.52 per share—$0.35 worse than analysts expected.

BlackRock Inc. purchased a new position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 918,357 shares of the company's stock, valued at approximately $140,343,000. BlackRock Inc. owned approximately 6.37% of Palvella Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of PVLA. Deutsche Bank AG purchased a new position in Palvella Therapeutics in the 2nd quarter worth approximately $1,809,000. Bank of New York Mellon Corp bought a new position in shares of Palvella Therapeutics during the second quarter valued at approximately $4,674,000. State of Wyoming bought a new position in shares of Palvella Therapeutics during the second quarter valued at approximately $134,000. Avidity Partners Management LP lifted its stake in Palvella Therapeutics by 262.7% in the first quarter. Avidity Partners Management LP now owns 70,000 shares of the company's stock worth $8,726,000 after acquiring an additional 50,700 shares during the period. Finally, Arete Wealth Advisors LLC purchased a new stake in Palvella Therapeutics in the first quarter worth $2,178,000. Hedge funds and other institutional investors own 40.11% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on PVLA shares. Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Chardan Capital upgraded Palvella Therapeutics to a "strong-buy" rating in a report on Tuesday, July 28th. Stephens reiterated an "overweight" rating and issued a $220.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Finally, Canaccord Genuity Group set a $232.00 price objective on Palvella Therapeutics in a research note on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $209.14.

Insider Activity

In other news, COO Kathleen Goin sold 4,302 shares of the business's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $152.21, for a total transaction of $654,807.42. Following the completion of the sale, the chief operating officer owned 2,154 shares of the company's stock, valued at $327,860.34. The trade was a 66.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is currently owned by insiders.

Palvella Therapeutics Stock Down 0.2%

Shares of Palvella Therapeutics stock opened at $149.97 on Friday. The company has a market cap of $2.16 billion, a price-to-earnings ratio of -31.05 and a beta of -0.17. Palvella Therapeutics, Inc. has a twelve month low of $49.81 and a twelve month high of $161.38. The company's 50 day moving average is $146.01 and its 200 day moving average is $126.90.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35). Sell-side analysts expect that Palvella Therapeutics, Inc. will post -6.36 EPS for the current fiscal year.

About Palvella Therapeutics

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source